Symbols / MDXG Stock $3.52 -0.56% MiMedx Group, Inc.

Healthcare • Biotechnology • United States • NCM
MDXG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Joseph H. Capper
Exch · Country NCM · United States
Market Cap 524.29M
Enterprise Value 385.09M
Income 30.70M
Sales 389.42M
FCF (ttm) 60.82M
Book/sh 1.73
Cash/sh 1.07
Employees 808
Insider 10d —
IPO Feb 12, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 17.60
Forward P/E 28.73
PEG 2.88
P/S 1.35
P/B 2.03
P/C —
EV/EBITDA 7.28
EV/Sales 0.99
Quick Ratio 4.62
Current Ratio 5.39
Debt/Eq 7.24
LT Debt/Eq —
EPS (ttm) 0.20
EPS next Y 0.12
EPS Growth —
Revenue Growth -33.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-29
ROA 8.54%
ROE 13.77%
ROIC —
Gross Margin 81.04%
Oper. Margin -27.21%
Profit Margin 7.88%
Shs Outstand 148.95M
Shs Float 117.99M
Insider Own 1.94%
Instit Own 73.72%
Short Float 7.09%
Short Ratio 4.89
Short Interest 8.39M
52W High 7.99
vs 52W High -55.94%
52W Low 3.03
vs 52W Low 16.17%
Beta 1.46
Impl. Vol. 3.55%
Rel Volume 1.40
Avg Volume 1.41M
Volume 1.98M
Target (mean) $6.50
Tgt Median $6.00
Tgt Low $5.00
Tgt High $8.00
# Analysts 6
Recom Strong_buy
Prev Close $3.54
Price $3.52
Change -0.56%
About

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.50
Mean price target
2. Current target
$3.52
Latest analyst target
3. DCF / Fair value
$7.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.52
Low
$5.00
High
$8.00
Mean
$6.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-30 main Citizens Market Outperform → Market Outperform $6
2026-04-20 main Citizens Market Outperform → Market Outperform $7
2026-04-17 main Craig-Hallum Buy → Buy $7
2026-02-23 init Citizens — → Market Outperform $10
2026-02-17 main Cantor Fitzgerald Overweight → Overweight $8
2026-01-20 main Lake Street Buy → Buy $10
2025-12-17 main Mizuho Outperform → Outperform $10
2025-07-31 main Cantor Fitzgerald Overweight → Overweight $12
2025-07-15 reit Cantor Fitzgerald Overweight → Overweight $11
2025-02-27 reit Cantor Fitzgerald Overweight → Overweight $13
2024-08-01 reit Cantor Fitzgerald Overweight → Overweight $11
2024-08-01 main Craig-Hallum Buy → Buy $12
2024-07-02 init Cantor Fitzgerald — → Overweight $11
2024-05-01 reit HC Wainwright & Co. Buy → Buy $11
2024-03-07 init Lake Street — → Buy $12
2024-03-01 main Mizuho Buy → Buy $14
2023-10-31 main Mizuho Buy → Buy $12
2023-10-27 init Craig-Hallum — → Buy $12
2023-08-02 main Mizuho Buy → Buy $12
2023-08-02 main HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest MDXG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 DOUGLAS RICE C Chief Financial Officer — 243,000 $4.50 $1,093,500
2026-03-10 HULSE WILLIAM FRANK IV General Counsel — 136,364 $4.50 $613,638
2026-03-10 MAERSK-MOLLER KIMBERLY Officer — 42,845 $4.50 $192,802
2026-03-04 CAPPER JOSEPH H Chief Executive Officer — 371,094 $0.00 $0
2026-03-04 DOUGLAS RICE C Chief Financial Officer — 74,163 $0.00 $0
2026-03-04 HULSE WILLIAM FRANK IV General Counsel — 74,987 $0.00 $0
2026-03-04 WHITLOW RICCI S Chief Operating Officer — 74,163 $0.00 $0
2026-03-04 MAERSK-MOLLER KIMBERLY Officer — 74,163 $0.00 $0
2025-11-06 MAERSK-MOLLER KIMBERLY Officer — 58,300 $7.42 $432,329
2025-06-18 OLSON TIFFANY Director — 28,609 $6.47 $185,100
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
418.63
+19.99%
348.88
+8.52%
321.48
+20.03%
267.84
Operating Revenue
418.63
+19.99%
348.88
+8.52%
321.48
+20.03%
267.84
Cost Of Revenue
73.01
+21.54%
60.07
+9.96%
54.63
+13.08%
48.32
Reconciled Cost Of Revenue
58.57
+6.89%
54.80
+5.44%
51.97
+15.56%
44.97
Gross Profit
345.62
+19.67%
288.81
+8.23%
266.84
+21.55%
219.53
Operating Expense
281.73
+22.76%
229.50
-0.10%
229.73
-1.93%
234.25
Research And Development
15.10
+22.33%
12.34
-2.56%
12.66
-0.28%
12.70
Selling General And Administration
266.19
+18.26%
225.09
+6.61%
211.12
+1.17%
208.67
Other Operating Expenses
—
-8.70
-268.04%
5.18
-57.49%
12.18
Total Expenses
354.74
+22.51%
289.57
+1.83%
284.36
+0.63%
282.57
Operating Income
63.89
+7.72%
59.31
+59.80%
37.12
+352.03%
-14.73
Total Operating Income As Reported
63.89
+8.53%
58.87
+58.60%
37.12
+352.03%
-14.73
EBITDA
78.77
+20.53%
65.35
+61.19%
40.54
+479.44%
-10.69
Normalized EBITDA
78.77
+19.71%
65.80
+62.29%
40.54
+479.44%
-10.69
Reconciled Depreciation
14.88
+146.33%
6.04
+76.28%
3.43
-15.30%
4.05
EBIT
63.89
+7.72%
59.31
+59.80%
37.12
+351.96%
-14.73
Total Unusual Items
0.00
+100.00%
-0.45
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-0.45
0.00
0.00
Special Income Charges
0.00
+100.00%
-0.45
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
0.45
0.00
0.00
Net Income
48.58
+14.52%
42.42
-27.15%
58.23
+292.83%
-30.20
Pretax Income
66.26
+15.65%
57.29
+87.03%
30.63
+255.13%
-19.75
Net Non Operating Interest Income Expense
2.93
+391.55%
-1.01
+84.42%
-6.46
-28.73%
-5.02
Interest Expense Non Operating
—
1.01
-84.42%
6.46
+28.73%
5.02
Net Interest Income
2.93
+391.55%
-1.01
+84.42%
-6.46
-28.73%
-5.02
Interest Expense
—
1.01
-84.42%
6.46
+28.73%
5.02
Other Income Expense
-0.56
+44.81%
-1.01
-3788.46%
-0.03
-550.00%
-0.00
Other Non Operating Income Expenses
-0.56
+1.24%
-0.56
-2073.08%
-0.03
-550.00%
-0.00
Tax Provision
17.68
+15.61%
15.30
+141.56%
-36.81
-17966.99%
0.21
Tax Rate For Calcs
0.00
+0.00%
0.00
+27.14%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.12
0.00
0.00
Net Income Including Noncontrolling Interests
48.58
+14.52%
42.42
-27.15%
58.23
+292.83%
-30.20
Net Income From Continuing Operation Net Minority Interest
48.58
+15.67%
42.00
-37.72%
67.44
+437.99%
-19.95
Net Income From Continuing And Discontinued Operation
48.58
+14.52%
42.42
-27.15%
58.23
+292.83%
-30.20
Net Income Continuous Operations
48.58
+15.67%
42.00
-37.72%
67.44
+437.99%
-19.95
Net Income Discontinuous Operations
0.00
-100.00%
0.42
+104.57%
-9.21
+10.08%
-10.24
Normalized Income
48.58
+14.77%
42.32
-37.24%
67.44
+437.99%
-19.95
Net Income Common Stockholders
48.58
+14.52%
42.42
-8.94%
46.59
+226.67%
-36.78
Otherunder Preferred Stock Dividend
0.00
0.00
-100.00%
4.89
0.00
Diluted EPS
0.32
+14.29%
0.28
-24.32%
0.37
+212.12%
-0.33
Basic EPS
0.33
+13.79%
0.29
-27.50%
0.40
+221.21%
-0.33
Basic Average Shares
147.79
+0.55%
146.98
+26.17%
116.50
+3.18%
112.91
Diluted Average Shares
149.72
+0.45%
149.05
+2.11%
145.96
+29.27%
112.91
Diluted NI Availto Com Stockholders
48.58
+14.52%
42.42
-8.94%
46.59
+226.67%
-36.78
Amortization
0.44
-42.61%
0.77
+0.39%
0.76
+8.70%
0.70
Amortization Of Intangibles Income Statement
0.44
-42.61%
0.77
+0.39%
0.76
+8.70%
0.70
Depreciation Amortization Depletion Income Statement
0.44
-42.61%
0.77
+0.39%
0.76
+8.70%
0.70
Depreciation And Amortization In Income Statement
0.44
-42.61%
0.77
+0.39%
0.76
+8.70%
0.70
Preferred Stock Dividends
—
—
6.75
+2.63%
6.58
Total Other Finance Cost
-2.93
-391.55%
1.01
-84.42%
6.46
—
Line Item Trend 2023-12-31 2021-12-31
Total Assets
239.05
—
Current Assets
164.26
—
Cash Cash Equivalents And Short Term Investments
82.00
—
Cash And Cash Equivalents
82.00
—
Receivables
53.87
—
Accounts Receivable
53.87
—
Gross Accounts Receivable
57.02
—
Allowance For Doubtful Accounts Receivable
-3.14
—
Taxes Receivable
—
0.74
Inventory
21.02
—
Raw Materials
0.82
—
Work In Process
8.52
—
Finished Goods
11.68
—
Prepaid Assets
5.62
-8.49%
6.15
Assets Held For Sale Current
0.00
—
Other Current Assets
1.75
—
Total Non Current Assets
74.79
—
Net PPE
9.11
—
Gross PPE
29.13
—
Accumulated Depreciation
-20.03
—
Properties
0.00
—
Machinery Furniture Equipment
1.99
—
Construction In Progress
1.79
—
Other Properties
17.21
—
Leases
8.14
—
Goodwill And Other Intangible Assets
24.70
—
Goodwill
19.44
—
Other Intangible Assets
5.26
—
Non Current Deferred Assets
40.78
—
Non Current Deferred Taxes Assets
40.78
—
Other Non Current Assets
0.20
—
Total Liabilities Net Minority Interest
96.33
—
Current Liabilities
46.01
—
Payables And Accrued Expenses
18.41
—
Payables
9.05
—
Accounts Payable
9.05
—
Other Payable
—
—
Current Accrued Expenses
9.36
—
Pensionand Other Post Retirement Benefit Plans Current
22.35
—
Current Debt And Capital Lease Obligation
1.00
—
Current Debt
1.00
—
Other Current Borrowings
1.00
—
Other Current Liabilities
4.25
—
Total Non Current Liabilities Net Minority Interest
50.32
—
Long Term Debt And Capital Lease Obligation
48.10
—
Long Term Debt
48.10
—
Other Non Current Liabilities
2.22
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
92.49
Stockholders Equity
142.72
—
Common Stock Equity
142.72
—
Capital Stock
0.15
—
Common Stock
0.15
—
Preferred Stock
—
0.00
Share Issued
146.23
—
Ordinary Shares Number
146.23
—
Treasury Shares Number
0.00
-100.00%
0.78
Additional Paid In Capital
276.25
—
Retained Earnings
-133.68
—
Treasury Stock
0.00
-100.00%
4.02
Total Equity Gross Minority Interest
142.72
—
Total Capitalization
190.82
—
Working Capital
118.25
—
Invested Capital
191.82
—
Total Debt
49.10
—
Net Tangible Assets
118.02
—
Tangible Book Value
118.02
—
Preferred Shares Number
—
0.10
Preferred Stock Equity
—
92.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
74.00
+11.79%
66.20
+147.24%
26.77
+249.64%
-17.89
Cash Flow From Continuing Operating Activities
74.00
+10.24%
67.13
+92.14%
34.94
+538.25%
-7.97
Cash From Discontinued Operating Activities
0.00
+100.00%
-0.93
+88.61%
-8.16
+17.73%
-9.92
Net Income From Continuing Operations
48.58
+15.67%
42.00
-37.72%
67.44
+437.99%
-19.95
Depreciation Amortization Depletion
14.88
+146.33%
6.04
+76.28%
3.43
-15.30%
4.05
Depreciation
—
2.28
-14.48%
2.67
-20.33%
3.35
Amortization Cash Flow
—
3.76
+393.70%
0.76
+8.70%
0.70
Depreciation And Amortization
14.88
+146.33%
6.04
+76.28%
3.43
-15.30%
4.05
Amortization Of Intangibles
—
3.76
+393.70%
0.76
+8.70%
0.70
Other Non Cash Items
1.90
+127.67%
-6.88
-465.66%
1.88
+4.44%
1.80
Stock Based Compensation
16.40
-3.17%
16.93
-0.15%
16.96
+49.71%
11.33
Provisionand Write Offof Assets
6.51
+994.96%
0.59
-58.94%
1.45
-48.62%
2.82
Asset Impairment Charge
—
—
1.45
-48.62%
2.82
Deferred Tax
8.71
-30.16%
12.47
+132.99%
-37.80
0.00
Deferred Income Tax
8.71
-30.16%
12.47
+132.99%
-37.80
0.00
Operating Gains Losses
—
1.40
+9240.00%
0.01
+188.24%
-0.02
Gain Loss On Sale Of PPE
—
—
0.01
+188.24%
-0.02
Change In Working Capital
-22.98
-322.89%
-5.43
+70.49%
-18.42
-129.80%
-8.01
Change In Receivables
-26.39
-934.25%
-2.55
+79.15%
-12.24
-106.11%
-5.94
Changes In Account Receivables
—
—
-12.24
-120.49%
-5.55
Change In Inventory
-1.53
+34.96%
-2.36
+69.93%
-7.84
-336.90%
-1.79
Change In Prepaid Assets
—
0.61
+314.13%
-0.28
+79.36%
-1.37
Change In Payables And Accrued Expense
13.48
+1833.43%
0.70
-22.90%
0.90
-32.84%
1.35
Change In Accrued Expense
11.36
+439.01%
2.11
+1641.32%
0.12
-76.13%
0.51
Change In Payable
2.12
+250.28%
-1.41
-280.08%
0.78
-6.67%
0.84
Change In Account Payable
2.12
+250.28%
-1.41
-280.08%
0.78
-6.67%
0.84
Change In Other Working Capital
0.29
+133.22%
-0.87
-75.05%
-0.50
-92.64%
-0.26
Change In Other Current Assets
-8.82
-2405.11%
-0.35
-128.12%
1.25
+475.98%
-0.33
Change In Other Current Liabilities
—
—
-0.50
-1407.89%
0.04
Investing Cash Flow
-6.89
+28.14%
-9.58
-344.69%
-2.15
+18.98%
-2.66
Cash Flow From Continuing Investing Activities
-6.89
+28.14%
-9.58
-344.69%
-2.15
+18.98%
-2.66
Net PPE Purchase And Sale
-1.03
+38.62%
-1.68
+15.30%
-1.99
-31.24%
-1.51
Purchase Of PPE
-1.03
+38.62%
-1.68
+15.30%
-1.99
-31.24%
-1.51
Sale Of PPE
—
—
0.00
-100.00%
0.02
Capital Expenditure
-1.03
+38.62%
-1.68
+15.30%
-1.99
-31.24%
-1.51
Net Business Purchase And Sale
-3.76
+52.12%
-7.86
0.00
0.00
Purchase Of Business
-3.76
+52.12%
-7.86
0.00
0.00
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-1.00
Purchase Of Intangibles
—
—
0.00
+100.00%
-1.00
Net Other Investing Changes
-2.09
-5397.37%
-0.04
+77.38%
-0.17
+85.34%
-1.15
Financing Cash Flow
-5.41
+84.17%
-34.20
-299.05%
-8.57
-1377.59%
-0.58
Cash Flow From Continuing Financing Activities
-5.41
+84.17%
-34.20
-299.05%
-8.57
-1377.59%
-0.58
Net Issuance Payments Of Debt
-1.00
+96.85%
-31.72
0.00
0.00
Issuance Of Debt
0.00
-100.00%
49.78
0.00
0.00
Repayment Of Debt
-1.00
+98.77%
-81.50
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
49.78
0.00
0.00
Long Term Debt Payments
-1.00
+98.77%
-81.50
0.00
0.00
Net Long Term Debt Issuance
-1.00
+96.85%
-31.72
0.00
0.00
Net Common Stock Issuance
-3.12
-18.06%
-2.64
0.00
+100.00%
-1.19
Common Stock Payments
-3.12
-18.06%
-2.64
0.00
+100.00%
-1.19
Repurchase Of Capital Stock
-3.12
-18.06%
-2.64
+72.24%
-9.52
-699.58%
-1.19
Proceeds From Stock Option Exercised
0.00
-100.00%
1.40
+40.12%
1.00
+53.15%
0.65
Net Other Financing Charges
-1.29
-4.52%
-1.24
-2280.77%
-0.05
-26.83%
-0.04
Changes In Cash
61.70
+175.27%
22.42
+39.66%
16.05
+175.95%
-21.13
Beginning Cash Position
104.42
+27.34%
82.00
+24.34%
65.95
-24.27%
87.08
End Cash Position
166.12
+59.10%
104.42
+27.34%
82.00
+24.34%
65.95
Free Cash Flow
72.97
+13.11%
64.52
+160.27%
24.79
+227.73%
-19.41
Interest Paid Supplemental Data
—
2.70
-55.29%
6.03
+32.06%
4.57
Income Tax Paid Supplemental Data
—
3.25
—
0.18
Issuance Of Capital Stock
—
—
—
0.00
Net Preferred Stock Issuance
0.00
0.00
+100.00%
-9.52
0.00
Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Payments
0.00
0.00
+100.00%
-9.52
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category